```html
TRAX Stock: First Tracks Biotherapeutics, Inc. - Comprehensive Overview
TRAX: First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX)
Key Finding: TRAX is the NASDAQ ticker for First Tracks Biotherapeutics, a clinical-stage biotechnology company focused on immunology therapies for autoimmune diseases, which has shown strong recent stock momentum amid positive analyst coverage following its 2026 rebranding and pipeline advancements.
Company Overview
Fact: First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, developing immunology therapeutics for autoimmune and inflammatory diseases.0
- CEO: Daniel R. Faga
- Employees: Approximately 104 (per one source)
- Website: firsttracksbio.com
- Sector/Industry: Healthcare / Biotechnology
Pipeline (Facts from Company Descriptions)
| Candidate | Target/Mechanism | Indication(s) | Stage |
|---|
| Rosnilimab | Selective pathogenic T cell depleter | Moderate-to-severe Rheumatoid Arthritis (RA) | Phase 2b completed |
| ANB033 | Anti-CD122 antagonist (IL-15/IL-2 receptor) | Celiac Disease (CeD), Eosinophilic Esophagitis (EoE); also Vitiligo mentioned in news | Phase 1b |
| ANB101 | BDCA2-modulating antibody (targets pDCs) | Autoimmune/inflammatory | Phase 1a |
Company History
Fact: The company was founded in 2019 and was formerly known as Biopharma Co., Inc.; it changed its name to First Tracks Biotherapeutics, Inc. in February 2026.0
Interpretation: The rebranding and NASDAQ listing (trading since approximately April 2026) likely reflect a strategic pivot or separation of assets, possibly linked to prior entities like AnaptysBio given overlapping pipeline names (ANB compounds).
Uncertainty: Exact pre-2026 corporate history and any spin-off details are not fully detailed in public sources; some references list founding as 2025.
Data Limitation: Public company history is short (post-April 2026 trading); pre-rebrand financials and operations are sparse in available data.
Recent News (2026)
- Multiple analyst initiations with Buy/Overweight ratings (e.g., Wells Fargo, Barclays, J.P. Morgan, Piper Sandler, H.C. Wainwright) with price targets around $30–$38.20
- Stock surged significantly in early July 2026 on momentum and clinical catalysts.
- Secondary offering filing (10.5M shares) noted in May 2026.
- Positive commentary on IL-15/CD122 pathway validation and upcoming ANB033 data.
Fact: Analyst consensus is "Strong Buy" with average 12-month target of $38.13.22
Stock Performance
Fact: As of early July 2026 trading sessions, the stock has exhibited high volatility typical of clinical-stage biotechs, with recent closes in the $20–$32 range following a surge from ~$17 in late April 2026.8
Recent Price History (Selected Daily Closes)
| Date | Close | Change | Volume |
|---|
| Jul 9, 2026 | ~29.82–32.40 (intraday high ~33.70) | +~25–53% | High (1.4M+) |
| Jul 8, 2026 | 20.77 | +5.01% | ~552K |
| Jul 7, 2026 | 19.78 | -1.30% | ~567K |
| Jul 2, 2026 | 19.30 | — | ~559K |
Performance Highlights:
- YTD Return: ~62% (vs. S&P 500 ~10%)
- Since April 21, 2026 (~$17): Up over 90% at peaks
- 52-Week Range: ~$14.72 – $33.70
- Market Cap: ~$690M – $1.13B (varies with price)
Interpretation: The sharp July 2026 rally appears driven by momentum trading, analyst upgrades, and biotech catalyst anticipation rather than fundamental revenue (pre-revenue company with net losses of ~$166M in 2025).
Data Limitation/Assumption: Performance data is based on snapshots from July 9–10, 2026 crawls; real-time prices fluctuate. Historical data limited as public listing began ~April 2026. No dividends expected. Past performance is not indicative of future results.
Links for More Information
Overall Data Limitations: Information compiled from web search results as of July 10, 2026. Biotech stocks are highly speculative; financials show ongoing losses with no commercial products. Verify latest data on official exchanges. No affiliation with any listed entities.
```